Inflazome said Sept. 11 that it closed a 15 million euro ($16.8 million) Series A financing round co-led by Novartis Venture Funds and Fountain Healthcare Partners. Inflazome, of Dublin, is developing orally available drugs to address inflammatory diseases.

Source: Businesswire